Skip to content
Screener
Generate Biomedicines, Inc. logo

Generate Biomedicines, Inc.

GENB

Generate Biomedicines, Inc. is a asset management company in the financial services sector trading on XNAS, led by CEO Michael T. Nally, with a market cap of $1.9B.

Market cap
$1.86B+30.0%
Revenue$32.5M—
Net income-$222.8M—
Free cash flow-$245.9M—
EPS (diluted)-$5.15—
Trailing twelve months · change vs. prior year

Earnings

Q2 2026 report

August 6, 2026
Revenue$6.3MBeat by $1.0MEPS-$0.52Miss by $0.01

Next report

Date not yet announced

Financials

Q2 2026

Income statement

See full
Revenue$6.3M-37.7%
Operating income-$71.6M-19.1%
Net income-$67.3M-28.3%
EPS (diluted)-$0.52+73.2%

Balance sheet

See full
Cash & equivalents$135.4M-12.3%
Total debt$62.6M—
Total equity$456.0M+188%
Total assets$561.7M—

Cash flow

See full
Operating cash flow-$57.9M-18.9%
CapEx$933.0K+506%
Free cash flow-$58.9M-20.4%

Valuation & ratios

Valuation

See full
Market cap$1.86B+30.0%
Enterprise value$1.78B—
P/S57.2×—

Returns & leverage

See full
Debt / equity0.1×—
Current ratio8.3×—

Profile

CountryUnited States of America
Listed2026
CEOMichael T. Nally
SectorFinancial Services
IndustryAsset Management
Websitegeneratebiomedicines.com
FilingsSEC EDGAR

FAQ

What is Generate Biomedicines, Inc.'s market cap?
Generate Biomedicines, Inc. (GENB) has a market capitalization of $1.9B and trades on XNAS.
What is Generate Biomedicines, Inc.'s revenue and profitability?
Generate Biomedicines, Inc. generated $32.5M in trailing twelve-month revenue with a net loss of $222.8M, representing a net margin of -685.9%, with free cash flow of -$245.9M. These figures are based on the Q2 2026 filing.
Where is Generate Biomedicines, Inc. headquartered?
Generate Biomedicines, Inc. is headquartered in United States of America. It has been publicly traded since 2026.